Feature Alcobra’s ADHD program moving to pediatrics With the recent start of the first of two pivotal trials in adults with attention deficit hyperactivity disorder (ADHD), Alcobra Pharma (NASDAQ:ADHD) is now turning its attention to advancing its pediatric ADHD program... January 14, 2014